Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
RALEIGH, N.C., April 18, 2016 -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this prestigious recognition. In 2015 PRA was also named the Best International Clinical Company of the Year.
|
|||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7401a9d9-079b-4ac0-9288-09a0f5b5c8d6
“This is an incredible honor for us,” said Michael Brooks, Executive Vice President, Product Registration, Americas. “PRA employees are passionate about their clinical development work and this award is recognition of their talent and dedication.”
PRA was well represented in the competition with 16 finalists in five different categories. Individual gold award recipients include:
- Experienced CRA: Raquel Amorim
- Strategic Partnership Team (PRA and CytRx): Stephanie Gonzalez, Sinead Pitts, Miriam Price
Organized by PharmaTimes, the Clinical Researcher of the Year competition is considered a key barometer of quality standards in the Clinical Research Organization (CRO) industry. The multi-stage competition is organized by an independent executive steering committee drawn from senior industry leaders from big and small pharma, leading CROs, and professional membership associations.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463 INVESTOR INQUIRIES: [email protected]
